NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

UBS starts Marex Group stock with Buy, highlights growth in derivatives market

EditorEmilio Ghigini
Published 20/05/2024, 10:22
© Reuters.
MRX
-

On Monday, Marex Group PLC (NASDAQ:MRX) stock, a global futures commission merchant, received a Buy rating from UBS, accompanied by a price target set at $27.00. The firm's initiation of coverage is based on a positive outlook for the company within the expanding global derivatives market.

Marex Group is expected to grow at a faster pace than the broader market, benefiting from its increasing scale as competitors pull back. UBS predicts that the derivatives market will grow at a high single-digit rate, and Marex is well-positioned to capitalize on this trend.

The company's growth trajectory is not solely reliant on market expansion; Marex is also expected to enhance its strong organic growth, projected at 9% by 2025, through strategic acquisitions. This approach is anticipated to bolster the company's market position and financial performance.

Despite the potential risks associated with interest rate fluctuations, UBS believes that these concerns are already reflected in Marex's current market valuation. The firm's analysis suggests that the stock price adequately accounts for the possible challenges arising from interest rate movements.

The UBS commentary underscores Marex's potential to outperform in its sector, despite the largest identified risk of exposure to interest rate changes. The firm's optimistic stance is based on the company's ability to leverage its growing scale and strategic acquisitions to exceed the growth of the global derivatives market.

InvestingPro Insights

Recent data from InvestingPro highlights Marex Group PLC's (NASDAQ:MRX) financial performance and market position. The company's adjusted market capitalization stands at $1.39 billion, with a P/E ratio that has improved to 9.33 in the last twelve months as of Q1 2024, down from 10.51. This suggests a potentially more attractive valuation for investors considering the stock.

InvestingPro Tips indicate that Marex's strong revenue growth of 17.76% in the last twelve months, coupled with a high gross profit margin of 86.85%, reflects the company's efficiency and potential for scalability. Moreover, the PEG ratio of 0.05 points to a stock that may be undervalued relative to its earnings growth, aligning with UBS's optimistic outlook.

For investors seeking further insights and analysis, InvestingPro offers additional tips on Marex Group and other companies in the derivatives market. By using the coupon code PRONEWS24, readers can get an extra 10% off a yearly or biyearly Pro and Pro+ subscription, gaining access to valuable investment tools and data to guide their decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.